Island Pharmaceuticals Repurposes Drug to Tackle Mosquito-Borne Diseases Globally

As the medical landscape for dengue fever lacks specific pharmaceutical treatments and features a limited-access vaccine, Island Pharmaceuticals Ltd is addressing the urgent need for effective solutions. Specializing in drug research and repurposing, the company focuses on developing preventative and therapeutic drugs for infectious diseases, with ISLA-101, a repurposed small molecule, as their lead asset originally developed by the wholly-owned subsidiary Isla Pharmaceuticals.